Literature DB >> 32289475

Head and Neck Cancer International Group (HNCIG) Consensus Guidelines for the Delivery of Postoperative Radiation Therapy in Complex Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN).

Sandro V Porceddu1, Christopher Daniels2, Sue S Yom3, Howard Liu4, John Waldron5, Vincent Gregoire6, Alisha Moore7, Michael Veness8, Min Yao9, Jorgen Johansen10, Hisham Mehanna11, Danny Rischin12, Quynh-Thu Le13.   

Abstract

Radiation therapy (RT) consensus contouring guidelines in the postoperative setting for complex cutaneous squamous cell carcinoma of the head and neck have been developed by expert clinicians in the field of head and neck and dermato-oncology and members of the Head and Neck Cancer International Group to assist radiation oncologists involved in the management of this disease. These guidelines present a set of principles used to define postoperative RT volumes and corresponding minimum doses after resection of all macroscopic tumor with or without microscopic residual disease. It is anticipated they will promote the harmonization of postoperative RT globally and contribute to a reduction in treatment variation among clinicians, allowing for RT quality and outcomes assessment across institutions.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32289475     DOI: 10.1016/j.ijrobp.2020.03.024

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  3 in total

Review 1.  The State of the Art of Radiotherapy for Non-melanoma Skin Cancer: A Review of the Literature.

Authors:  Sofian Benkhaled; Dirk Van Gestel; Carolina Gomes da Silveira Cauduro; Samuel Palumbo; Veronique Del Marmol; Antoine Desmet
Journal:  Front Med (Lausanne)       Date:  2022-06-27

Review 2.  Reporting quality of clinical practice guidelines on head and neck cancer: a systematic review.

Authors:  Jiabao Hou; Qiangqiang Guo; Hanqiong Zhou; Xuan Wu; Lidan Hao; Zhe Zhang; Shuxiang Ma; Jing Han; Zhen He; Zhensheng Liu; Yaolong Chen; Qiming Wang
Journal:  Transl Cancer Res       Date:  2022-06       Impact factor: 0.496

3.  Combination RSL3 Treatment Sensitizes Ferroptosis- and EGFR-Inhibition-Resistant HNSCCs to Cetuximab.

Authors:  Shujie Liu; Shuai Yan; Jie Zhu; Ruiqing Lu; Chujie Kang; Kang Tang; Jinfeng Zeng; Mingmei Ding; Zixiang Guo; Xianxin Lai; Yinan Jiang; Siqing Wu; Lihua Zhou; Litao Sun; Zhong-Wei Zhou
Journal:  Int J Mol Sci       Date:  2022-08-12       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.